fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19a randomized clinical trial.
fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19a randomized clinical trial.
conclusions and relevance: in this preliminary study of adult outpatients with symptomatic covid-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days.", "the use of fluvoxamine for the treatment of covid-19 is considered investigational, which means the us food and drug administration has not approved it for this use.", "ivermectin to prevent hospitalizations in patients with covid-19 (ivercor-covid19): a structured summary of a study protocol for a randomized controlled trial.", 


































"clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% ci, 1.8%-16.4%] from survival analysis; log-rank p = .009).")